Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia-Reference-Cited by-同舟云学术

Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia

Published:2011-04-18 Issue:4 Volume:6 Page:e18925
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Catellani Silvia,Pierri Ivana,Gobbi Marco,Poggi Alessandro,Zocchi Maria Raffaella

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leukemia.;S O'Brien;J Natl Compr Canc,2009

2. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia.;A Hochhaus;Leukemia,2009

3. Imatinib Mesylate – Uncovering a fast track to adaptive immunity.;MJ Smyth;New Engl J Med,2006

4. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.;C Borg;J Clin Invest,2004

5. Interferon-producing killer dendritic cell provide a link between innate and adaptive immunity.;CW Chan;Nature Medicine,2006

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity;Journal of Clinical Medicine;2024-04-18

2. Cancer stem cell, chromosomal instability, and cancer immunity;Exploration of Immunology;2024-04-02

3. Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients;Journal of Clinical Medicine;2022-08-24

4. Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?;Cancers;2021-08-16

5. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia;Frontiers in Oncology;2019-10-09